Exchange: NASDAQ·Updated 07:49 PM EST
IVA logo

IVA Inventiva - ADR

$3.14
$0.31
(8.99%)
Today
Closed $3.14
$0.04
(1.27%)
After Hours
EarningsApr 1
Mkt Cap$750.78M
Vol3.02M

About IVA

Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.
68

Bullish Sentiment

How do you feel about IVA?

POPEYE832
$IVA $IVA – Inventiva is clearly preparing for a US commercial launch. Inventiva is recruiting for two key leadership positions: * VP, Head of US Market Access: pricing, reimbursement, payer negotiations and commercial strategy. * Executive Director, US Trade & Distribution: wholesalers, specialty pharmacies, supply chain and launch logistics. These aren’t just research positions. They’re critical roles for building a fully operational US commercial infrastructure.
10
POPEYE832
$IVA Key Takeaways from the UBS Discussion on November 17, 2026 – $IVA - Data Quality Control: Data verification and quality checks are currently underway. Teams are actively working on the process. - Results Timing: Q4 2026 reaffirmed. Management would prefer to avoid Christmas week. - Launch and Financing: FDA filing targeted for H1 2027, with a potential launch in 2028. Inventiva plans to commercialize independently in the US and Europe. Management may seek additional funding after the readout, depending in part on the stock price reaction to the announcement. - Expected Results: An 18-percentage-point placebo-adjusted difference on the dual primary endpoint would be considered a commercial success. Management hopes to do even better. The dropout rate is lower than the initially assumed 30%.
7
Jyoudoit
Breaking 🚨 $IVA Inventiva listed 15 new job openings on LinkedIn today. Not suggesting this means the data are positive. Just an interesting development worth keeping an eye on. DYOR. NFA.
10
POPEYE832
$IVA $IVA Starting today, only 45 NASDAQ trading sessions remain until the end of Q4. Assuming the Phase 3 results are guaranteed to be released by year-end and every trading day is equally likely, the cumulative probability increases by 2.22 percentage points per session.
9
BioRich
$IVA Many positives stacking for $IVA, now we just need the excellent fibrosis data we expect.
8
Twitwizard1978
$IVA Nothing is ever guaranteed. But when you consider the insider cluster purchases with the massive 32-million-share accumulation wave from professional biotech asset managers here in the states with big players like Caligan Partners, LP 8.16 million shares, Samsara BioCapital, LLC 6.31 million shares, Paradigm Biocapital Advisors LP 4.00 million shares, Andera Partners 3.63 million shares, ADAR1 Capital Management, LLC 3.61 million shares, Millennium Management LLC 3.51 million shares, and then little’ol me with 1000 shares, and on and on ... the data shows that these deep pocket professional biotech players are drawing the exact same conclusion as the board.. that the risk-reward factor is highly favorable. Im all in!!! Shorties will try to convince you this is trash but don’t listen… You may win or you may lose.. but the odds are in your favor bulls! And if your just playing with house money, even better 😉
8
Jyoudoit
$IVA $IVA | Inventiva is making some serious moves ahead of NATiV3. Suzanne Delaney joins as Head of U.S. Commercial, bringing 25+ years of experience, including senior leadership roles at Akebia Therapeutics, Sage Therapeutics and AstraZeneca, where she helped drive the Symbicort franchise. This isn’t just another executive appointment. It’s a strong signal that Inventiva is positioning itself for potential U.S. commercialisation of lanifibranor. For investors, this adds another layer of confidence to the execution story. The Phase 3 data still needs to deliver, but the pieces are increasingly falling into place. Bullish on the direction.
7
Jyoudoit
$IVA $431.3M in Rezdiffra sales in one quarter, up 50% YoY. Hats off to $MDGL for opening this market for MASH patients. This is why I’m excited for $IVA. Doctors are already looking for MASH and prescribing an oral treatment. Imagine a strong NATiV3 readout landing in that market.
6
Onmoonway
$IVA +25% in a week! Back to back green days. Frequent big block of trades recently. Ph3 result in less than a month.
6
seeworld8
$IVA this is an educated gamble, good luck to all. Hope recent drop is not due to insider selling
5
Windog
$IVA why did they make announcement at AASLD that they postponed their presentation yesterday and will be providing in Jan.?
1
1
Stockseeking
$IVA Manipulation is almost over, will go back to 4 by tomorrow and then up leading to 3-4 x after positive result
3
Cresskill198
$IVA adding. Fxxk the market makers! If the phase 3 follows the phase 2, it’s huge and the buyout will follow.
3
Stockseeking
$IVA added 3k, for a total of 10k, no more adding, that is all I can risk with >90% of chance to 3x or losing >70%
3
Twitwizard1978
$IVA He said sector rotation lol... Is this claim valid? No, the timeline and scale are completely distorted. While sectors rotate over months and quarters, they do not "implode tomorrow" to immediately pump an isolated, micro-cap biotechnology stock. This is classic "stock market cheerleading." The commenter is using sophisticated financial terms ("sector rotation") to sound authoritative while making a wild prediction. Treat Inventiva ($IVA) purely as a binary biotech play—its stock price will likely live or die by its upcoming Phase 3 liver disease data, completely independent of what happens to Bitcoin or Nvidia tomorrow.
3
Cresskill198
$IVA is this a tech company? Why stupid algo align this with it? The company’s fate is dependent upon the phase 3 data coming out soon, not on correction from crazy valued tech companies.
2
Doom_Gloom_AR
$IVA long here - highly likely to be stat sig on fibrosis reduction, the risk on this readout is saftey, swelling weight gain - I'm thinking going from f4->f3 is more important than anything else, because your dead pretty quick if your f4.
2
Bainv
$IVA do they usually report data afterhour on US market after they were listed on nasdaq?
1
SteadyTrade55
$IVA lol. People here abjectly refuse to sell their shares even in the face of market Armageddon lol
1

Advertisement|Remove ads.